-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
“Innovative ‘API + Formulation’ Approach Yields Substantial Results! Shijiazhuang Sihua Pharmaceutical Group Receives Concurrent Approval for Two APIs—Dihydroxypropylxanthine and Acipimox”
Category:
TIME：2025-04-23
Continuous innovation and steady accumulation ultimately lead to breakthroughs. On April 22, following the approval of three new products—dapagliflozin/metformin extended-release tablets (I) and arginine ibuprofen granules (0.2 g/0.4 g)—Shijiazhuang Sihua Pharmaceutical Group saw its subsidiary, Hebei Guangxiang Pharmaceutical Co., Ltd., successfully take over and secure approval on the same day for two active pharmaceutical ingredients it had developed and submitted: theophylline dihydrate and acipimox. This marks another significant achievement in the company’s pursuit of integrated development across both API and formulation segments.
According to available information, theophylline dihydrate is indicated for relieving wheezing symptoms in bronchial asthma, asthmatic bronchitis, and obstructive emphysema, and may also be used for wheezing caused by cardiogenic pulmonary edema. Acipimox can be employed as monotherapy or adjunctive therapy to reduce triglyceride levels in patients whose response to other treatments, such as statins or fibrates, is inadequate; it is indicated for the following conditions: hypertriglyceridemia (Fredrickson type IV hyperlipoproteinemia) and combined hypercholesterolemia and hypertriglyceridemia (Fredrickson type IIb hyperlipoproteinemia).
To date, the Group has received approval for a total of 74 bulk and specialty APIs, with Guangxiang Pharmaceutical accounting for 43 of these approvals. Previously, acipimox capsules were approved for registration in February 2025. The recent approval of acipimox API will further enhance the Group’s integrated “API-plus-formulation” product portfolio, providing robust assurance for subsequent market commercialization.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
